Translating CAP Evidence into Clinical Practice

The management of community-acquired pneumonia (CAP) is advancing fast, being informed by updated guidelines, improved severity assessment, and renewed evidence for macrolides. Updated guidance has refined treatment strategies and antimicrobial optimisation approaches aimed at enhancing clinical outcomes while promoting antimicrobial stewardship. Emerging data in severe CAP management support macrolide combination therapy with the ACCESS trial showing enhanced early clinical response, lower progression to respiratory failure, and immunomodulatory benefits. Real-world outcomes, economic analyses, and immunoproteomic and transcriptomic studies further delineate the clinical and biological impact of macrolide therapy. Collectively, these developments integrate best practices for diagnosis and personalised management across care settings.